Compare the latest tech products

Biomarker research could lead to finger-prick cancer test


March 28, 2011

Biomarker research could lead to finger-prick cancer test (Photo: AlishaV via Flickr)

Biomarker research could lead to finger-prick cancer test (Photo: AlishaV via Flickr)

A new interdisciplinary breakthrough could see cancer being diagnosed through a quick finger-prick test. After five years of research, the team of biologists, clinical oncologists, pathologists and information scientists from ETH Zurich, University Hospital Zurich and the Cantonal Hospital of St. Gallen have determined a biomarker for prostate cancer – a particular pattern of proteins in the blood that indicate the presence of cancerous disease.

A common precursor to prostate cancer in both mice and men is the inactivation of the "Pten" gene, which can lead to uncontrolled cell growth. Thus mouse models were used in the hope that subsequent steps would be common between species. The researchers began by examining prostate surface proteins and comparing protein sets in both healthy and cancerous mice that had developed the disease following Pten inactivation. From this they determined a pattern of proteins that is typical of the mutated version of Pten and thus also for prostate cancer.

Examining tissues and serum samples from human prostate cancer sufferers and a control group, and using the list of specific proteins drawn up using the mouse model, the scientists were able to identify 39 corresponding proteins in humans that indicated the presence of cancer. The information scientists then calculated the four most reliable proteins as cancer indicators using 20,000 models.

"We then used this biomarker pattern to examine a cohort of patients whose blood had never previously been analyzed," says Wilhelm Krek, professor of Cell Biology at ETH Zurich. "We were able to predict with precision, stability and reproducibility whether they were suffering from prostate cancer."

It is presumed that the onset of cancer is often triggered by a mutation, such as the deactivation of a gene, which can lead to a change in the protein pattern of the affected organ. Separating off surface proteins of certain tissues allows 20 percent of these protein patterns to be detected in the serum, allowing a reliable method of diagnosis.

Currently, cancer is diagnosed by tumor antigens in the blood, but these methods are often misleading and can involve expensive and painful biopsies.

The identification of a reliable biomarker that indicates cancer has been the subject of advanced studies by scientists for many years, but often other factors were found to skew the results. "The protein patterns that were determined may have reflected the patients' eating habits, but were unable to provide any indication about whether or not a cancerous disease was present," explains Krek. By contrast, the biomarker pattern method is extremely precise, and even conveys information about the type of tumor which helps to identify the best therapy to combat it. Other cancer

The biomarker signature needs to be validated in further clinical trials, and the ETH Zurich spin-off company Proteomedix AG is currently developing a diagnosis kit. However it is hoped that the study can be applied to other forms of cancer, bringing better early detection and more focused therapy. The collaborative work by the interdisciplinary team highlights the progress that can be made when groups of scientists work together. The work is to be published in the next issue of PNAS.


\"We were able to predict with precision, stability and reproducibility whether they were suffering from prostate cancer.\" I don\'t believe it. Probably they were able to predict with precision, stability and reproducibility whether the subjects had prostate cancer,\" but if they were suffering, it would be pretty advanced anyway. I am 66 years old. If I had the very common case of early-stage prostate cancer that would take forty years to give me symptoms (let alone kill me) I would assume that something else would kill me first, and do about it exactly what I do about my symptomless gall stones: keep the surgeons at a safe distance. To decide whether it is a slow case is likely to involve \"expensive and painful biopsies\" without good predictive value. Why start? There is just one reason to take this test. Your health care provider would like the money.

Facebook User

Tim Pouston is correct.

The real problem is not finding prostate cancer, it is identifying early enough to treat those prostate cancers that will metastacize (spread) within the man\'s normal lifespan. We are already finding and treating too many prostate cancers that aren\'t going to cause any problems. So it is misleading to think that this test will be a great leap forward.

One possible benefit might be a reduction in the number of biopsies being done on men who don\'t have prostate cancer. We will be waiting for further results, like all the other \"new tests\".


And also gentlemen, please be aware that a biopsy of the prostate is the best way to spread the cancerous cells in your body by releasing them to the blood stream - and it is inevitable that this happens.

I feel so silly for having the prostate biopsy done, having been assured by the doctors that there is no danger. But now I know that there is a significant danger. Don\'t let them touch your prostate, especially if you do have a cancer - which you of course can\'t know, so it\'s safer to presume that you do have it - and then do absolutely nothing.

There must be a better way, in 21st century, to cure prostate cancer other than making you impotent, incontinent and never able to enjoy the wonderful joys of ejaculation again. We are still living in medicine\'s Stone Age where the cure is worse than the disease.

Post a Comment

Login with your Gizmag account:

Related Articles
Looking for something? Search our articles